1.. Introduction {#s1}
================

Parkinson\'s disease (PD) is the second most common neurodegenerative disease \[[@RSOS171177C1]\]. PD varies in its presentation; symptoms may include disturbed sleep, depressive symptoms, apathy and cognitive complications in addition to classic motor features such as bradykinesia, rigidity and tremor \[[@RSOS171177C2]\]. Deep brain stimulation (DBS) of the subthalamic nucleus (STN DBS) can improve many of the motor symptoms \[[@RSOS171177C3]\], but changes in mood, motivation and cognition also occur and may be either beneficial or detrimental to the patient \[[@RSOS171177C4]\]. In fact, clinical results vary substantially among patients. Some evidence suggests that the location of stimulation within or around the STN may contribute to the motor, mood and cognitive effects of STN DBS, given its relatively segregated anatomical connections to motor, somatosensory and limbic neural circuits \[[@RSOS171177C5]\]. However, the methods used to test this hypothesis in the past have had limitations, including not examining the entire relevant volume of the brain \[[@RSOS171177C6]--[@RSOS171177C8]\], not determining the statistical significance of relationships between behaviour and DBS site \[[@RSOS171177C9]--[@RSOS171177C12]\], or not correcting for type 1 errors due to the multiple comparisons inherent in three-dimensional (3D) statistical maps with many data points (i.e. voxels) \[[@RSOS171177C13]\]. Some studies examined the effects of DBS on neuronal response with reference to the volume of tissue predicted to be activated based on electrical field models \[[@RSOS171177C14]\]. We combined the anatomical location of the stimulated electrode with clinical data to produce statistical images that demonstrate DBS locations associated with improvement and worsening of each measured symptom, and determined overall statistical significance from these images using a permutation approach \[[@RSOS171177C15]\]. This method avoids the issues noted above, and identifies whether location relates to clinical response in a statistically rigorous manner controlled for multiple comparisons.

Using this method, we previously examined the acute effects of unilateral STN DBS in PD, using each person\'s clinically optimized stimulation parameters and electrode contacts. Mood, cognition and motor function were assessed with DBS OFF and ON at least 8 h after the most recent dose of PD-related medication. The 3D analyses suggested that location of stimulation was significantly associated with mood, cognition and some motor outcomes \[[@RSOS171177C15]\]. Most motor measures improved with DBS everywhere in the STN, while a few motor, cognitive and mood measures differed depending on the location of stimulation. A limitation of that study was that stimulation parameters (e.g. voltage) differed across individuals, which could differentially impact behaviour. The stimulation parameters used and the contact chosen were determined through the clinical programming process, so the results could not distinguish whether all participants would have had similar motor benefit with DBS anywhere in the STN, or whether the ideal DBS location simply varied by participant. Therefore, in this new study, all participants with PD had separate, blinded, unilateral stimulation conditions at both dorsal *and* ventral STN locations chosen by brain imaging blind to clinical results. All stimulation parameters were maintained across condition and participant. We hypothesized that our findings would be qualitatively similar to those in our previous report, but that effects might be more striking due to the consistent stimulation parameters and the more uniform approach to selecting DBS locations in both dorsal and ventral STN.

2.. Material and methods {#s2}
========================

2.1.. Participants {#s2a}
------------------

Seventy-four patients with PD were recruited through the Movement Disorders Center at Washington University St. Louis School of Medicine (WUSM), St. Louis, MO, USA. Inclusion criteria included bilateral STN DBS therapy for clinically definite PD, as previously defined \[[@RSOS171177C16]\] based on established criteria \[[@RSOS171177C17],[@RSOS171177C18]\]. Patients waited at least 3 months after DBS implantation to participate in the study. Exclusion criteria included neurological conditions such as history of stroke; history of serious head injury (any neurological sequelae, open skull fracture or hospitalization); history of definite encephalitis or oculogyric crises; drug-induced parkinsonism; sustained remission from PD; strictly unilateral features after 3 years; supranuclear gaze palsy; cerebellar signs (ataxia of gait or limbs, central nystagmus, scanning dysarthria or truncal ataxia); early severe autonomic involvement; early severe dementia (within the first year of onset) with disturbances of memory, language and praxis; extensor plantar reflex; Mini Mental State Examination score less than 24 \[[@RSOS171177C16]\]; any defect on brain imaging (such as infarcts, brain tumour, hydrocephalus or congenital defects like lissencephaly but not cavum septum pellucidum); or MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) exposure, for which patients were screened prior to DBS surgery. The demographics of the participants of the study are shown in [table 1](#RSOS171177TB1){ref-type="table"}. Table 1.Demographics and clinical characteristics of 74 research participants with PD. CD-LD, carbidopa--levodopa; CD-LD ER, carbidopa--levodopa extended release; DA, dopamine; MAO, monoamine oxidase; COMT, catechol-*O*-methyl transferase, UDPRS, Unified Parkinson Disease Rating Scale.mean (s.d., range)age (years)62 (9.1, 43--80)education (years)^a^15.1 (2.7, 10--20)disease duration (years)12.4 (5.1, 0.51--26.5)time since STN DBS surgery (months)18.2 (16.1, 3--77)distributionsex50 male, 24 femaleethnic origin^b^65 white, 4 Native American/Alaskan Native, 1 African American, 1 Asian, 2 unknown/othermore affected side, by UPDRS III subscore41 right, 33 leftdominant hand^b^65 right, 7 left, 1 ambidextrouscurrent PD medication^c,d^74 CD-LD, 12 CD-LD ER, 33 DA agonist^e^, 7 MAO inhibitor, 32 COMT inhibitor, 25 benzodiazepines, 40 amantadine, 7 antidepressants^f^, 21 other drugs[^4][^5][^6][^7][^8][^9]

2.2.. Subthalamic nucleus deep brain stimulation electrode contact selection {#s2b}
----------------------------------------------------------------------------

The side of the brain contralateral to the more affected side of the body was stimulated. The more affected side of the body was defined by the side of the body that had higher Unified Parkinson Disease Rating Scale (UPDRS) scores in the off-medication, off-stimulation state \[[@RSOS171177C6]\]. The DBS electrode contacts for each individual were placed in atlas space using a validated method \[[@RSOS171177C19],[@RSOS171177C20]\] to identify the contact locations with respect to the STN. Dorsal and ventral STN DBS contacts were chosen for each participant based on the examination of their position in atlas space. Specifically, a contact within 2 mm of the ventral STN border was chosen as the ventral contact, and a contact within 2 mm of the dorsal STN border was chosen as the dorsal contact, ideally with one unused contact in between \[[@RSOS171177C6]\].

2.3.. Stimulation protocol {#s2c}
--------------------------

Participants stopped PD medications at midnight before the morning of the study. The UPDRS ratings and mood and cognitive tasks were completed during separate dorsal, ventral and OFF STN DBS sessions over the course of one day. The order of the dorsal, ventral and OFF sessions was randomized and blinded to the participants and raters. The voltage, frequency and pulse width were 2.5 V, 185 Hz and 60 µs, respectively, for most participants. However, 14 participants experienced side effects from 2.5 V and so the voltage was reduced to 1.6--2.3 V.

2.4.. Measurements {#s2d}
------------------

Motor symptoms were rated with the UPDRS, part III-motor, administered by a trained clinician blind to stimulation condition. UPDRS subscale scores for bradykinesia (sum of scores from finger taps, hand movements, rapid movement of hands and leg agility), rigidity, tremor at rest and total were summed contralateral to the stimulated side of the brain. The UPDRS 'body bradykinesia and hypokinesia\' item score was considered separately (hereinafter 'body\').

Cognition was evaluated via the spatial delayed response (SDR) and the Go/No-Go (GNG) tasks. The SDR task assesses short-term and working memory for spatial information, and was performed as described previously; the variable of interest was the distance between actual and recalled (after a 15 s delay) cue locations, or error \[[@RSOS171177C21],[@RSOS171177C22]\]. The GNG task assessed the ability to select and inhibit a pre-potent motor response appropriately under conditions of high pre-potent response strength \[[@RSOS171177C23]\], and was performed as described previously \[[@RSOS171177C6]\]. The discriminability index, Pr, was the outcome measure, defined as the proportion of hits minus the proportion of false alarms. Only data from participants who reached a criterion of Pr \> 0.5 in the OFF DBS condition were included in the analyses.

Self-rated current affective state was assessed using visual analogue scales (VASs) based on the circumplex model of emotion \[[@RSOS171177C24]\] and transformed to valence and arousal scores, as described previously \[[@RSOS171177C15],[@RSOS171177C25]\]. Separate scores for anxiety and apathy were also measured using a VAS \[[@RSOS171177C8]\]. Higher scores on valence, anxiety and apathy represented, respectively, happier, less anxious and less apathetic states.

2.5.. Primary statistical analyses {#s2e}
----------------------------------

### 2.5.1.. Outliers {#s2e1}

In the datasets for all measures in both statistical analyses---univariate and 3D---outliers were defined as data values more than 3 s.d. from the mean. The datasets and statistical outcomes shown are based on the datasets with these outliers removed.

### 2.5.2.. Univariate statistics {#s2e2}

Dorsal, ventral and OFF DBS scores for each measure, including total contralateral UPDRS, tremor at rest, rigidity, bradykinesia, SDR error in mm, GNG Pr, valence, arousal, apathy and anxiety, were compared using separate repeated-measures ANOVAs. If the ANOVA *p*-value was statistically significant, dorsal-OFF, ventral-OFF and dorsal--ventral difference scores for the corresponding measures were compared with 0 using one-sample *t*-tests. We repeated the ANOVAs for participants who received 2.5 V STN DBS, excluding participants who received less than 2.5 V STN DBS. The threshold for statistical significance for ANOVAs was *α* = 0.005, reflecting Bonferroni correction for multiple comparisons (0.05/10 comparisons). The threshold for statistical significance for one-sample *t*-tests was *α* = 0.05.

### 2.5.3.. Statistical mapping of deep brain stimulation effects to subthalamic nucleus anatomy {#s2e3}

Our mapping method is described in detail in Eisenstein *et al*. \[[@RSOS171177C15]\]. Briefly, four statistical maps were generated for each measure. (i) An *N* image shows the number of stimulated contacts that contributed dorsal or ventral DBS difference scores to each voxel of the map, i.e. within 1.3 mm. Voxels with *N *\< 6 were not included in further steps. (ii) A weighted mean image, containing the weighted mean difference scores across participants, with nearer contacts weighted higher. (iii) A *t* image depicting weighted *t* values derived from single-sample *t* tests comparing the mean difference scores (dorsal--OFF or ventral--OFF) at each voxel with zero. (iv) A *p*-image containing *p*-values for the *t* test at each voxel. We repeated the statistical mapping for participants who received 2.5 V STN DBS, excluding participants who received less than 2.5 V STN DBS.

### 2.5.4.. Type 1 error correction for multiple comparisons and sample bias {#s2e4}

To test whether the anatomical location of the active DBS contact significantly contributed to clinical effects, we used a permutation test as previously described \[[@RSOS171177C15]\]. Briefly, for each measure, a summary score reflecting the extent and amplitude of significant voxels in the *p*-image was generated, and compared with 1000 summary scores generated similarly but from randomly chosen pairings of the active contact locations and difference scores. We considered a *p*-value ≤ 0.05 (i.e. a summary score that would place it in the top 50 of the 1000 random data permutations) to indicate that DBS location significantly contributed to a measure\'s difference scores. We repeated type 1 error correction for participants who received 2.5 V STN DBS, excluding participants who received less than 2.5 V STN DBS.

3.. Results {#s3}
===========

3.1.. Distribution of contacts {#s3a}
------------------------------

The stimulated contacts from 74 participants, each with a dorsal STN and ventral STN contact, are shown in [figure 1](#RSOS171177F1){ref-type="fig"}. All contacts were located within 2 mm of the STN border. Figure 1.Distribution of contacts included in the analyses shown as green (dorsal) and purple (ventral) spheres, with paired contacts of each participant indicated by yellow connecting rods, and blue transparent regions indicating the subthalamic nucleus (STN).

3.2.. Univariate results {#s3b}
------------------------

The effects of dorsal or ventral STN DBS on mood, cognitive and motor measures (irrespective of 3D active contact location) are described in [table 2](#RSOS171177TB2){ref-type="table"}. Ventral or dorsal DBS significantly improved all UPDRS motor scores, anxiety, valence and apathy. Unilateral STN DBS did not significantly affect the mean scores for the GNG and SDR cognition tests. Dorsal scores differed significantly from ventral scores for anxiety and rigidity, which both improved more with ventral STN DBS than with dorsal STN DBS. Results were similar when participants stimulated at less than 2.5 V were excluded from analyses, except that the univariate effects of dorsal STN DBS did not differ significantly from those of ventral STN DBS on any measure (electronic supplementary material, table 1). Table 2.Outcome measures, by STN DBS conditions and DBS site (dorsal versus ventral STN).rmANOVA resultmean difference (s.d.)d.f.sig. (two-tailed)*mood and motivation*^a^*F*~2,138~ = 13.7, *p* \< *0.001***\***anxiety: dorsal versus OFF6.2 (16.0)69*0.002*anxiety: ventral versus OFF9.5 (17.0)69*\<0.001*anxiety: dorsal versus ventral−3.3 (12.9)69*0.04F*~2,138~ = 1.9, *p* = 0.15arousal: dorsal versus OFF0 (0.2)arousal: ventral versus OFF−0.03 (0.2)N/AN/Aarousal: dorsal versus ventral0.03 (0.1)*F*~2,138~ = 11.1, *p* \< *0.001*\*valence: dorsal versus OFF0.1 (0.2)69*0.001*valence: ventral versus OFF0.2 (0.3)69\<*0.001*valence: dorsal versus ventral−0.05 (0.2)690.12*F*~2,138~ = 4.8, *p* =* 0.009*apathy: dorsal versus OFF7.1 (20.8)69*0.006*apathy: ventral versus OFF6.3 (23.7)69*0.03*apathy: dorsal versus ventral0.8 (17.9)690.7*cognition*^b^*F*~2,132~ = 1.5, *p* = 0.2GNG: dorsal versus OFF0.03 (0.2)N/AN/AGNG: ventral versus OFF0.01 (0.2)GNG: dorsal versus ventral0.02 (0.1)*F*~2,136~ = 1.4, *p* = 0.2SDR: dorsal versus OFF−1.0 (8.5)N/AN/ASDR: ventral versus OFF−1.3 (9.3)SDR: dorsal versus ventral0.33 (9.31)*movement*^c^*F*~2,138~ = 30.9, *p* \< *0.001***\***bradykinesia: dorsal versus OFF−1.6 (2.1)69\<*0.001*bradykinesia: ventral versus OFF−1.8 (2.2)69\<*0.001*bradykinesia: dorsal versus ventral0.2 (1.9)690.8*F*~2,140~ = 27.1, *p* \< *0.001***\***body: dorsal versus OFF−0.5 (0.6)70*\<0.001*body: ventral versus OFF−0.5 (0.6)70*\<0.001*body: dorsal versus ventral−0.01 (0.6)700.5*F*~2,140~ = 38.5, *p* \< *0.001***\***rigidity: dorsal versus OFF−0.8 (1.1)70*\<0.001*rigidity: ventral versus OFF−1.1 (1.2)70*\<0.001*rigidity: dorsal versus ventral0.3 (0.9)70*0.006F*~2,140~ = 30.2, *p* \< *0.001***\***tremor at rest: dorsal versus OFF−1.2 (1.6)70*\<0.001*tremor at rest: ventral versus OFF−1.2 (1.8)70*\<0.001*tremor at rest: dorsal versus ventral−0.01 (1.1)700.9*F*~2,140~ = 75.3, *p* \< *0.001***\***UPDRS: total dorsal versus OFF−4.2 (3.6)70*\<0.001*UPDRS: total ventral versus OFF−4.2 (3.5)70*\<0.001*UPDRS: total dorsal versus ventral0.02 (2.7)701.0[^10][^11][^12][^13]

3.3.. Subthalamic nucleus deep brain stimulation effects depend on deep brain stimulation site {#s3c}
----------------------------------------------------------------------------------------------

For the analysis based on 3D location of DBS, statistical significance for each measure is shown in [table 3](#RSOS171177TB3){ref-type="table"}. DBS location significantly contributed to the effects of STN DBS on body, rigidity and tremor at rest. Statistical maps for these effects are shown in [figure 2](#RSOS171177F2){ref-type="fig"}. Results were similar after excluding participants who could not tolerate 2.5 V DBS. Figure 2.Weighted mean image (i), *p*-image (ii) and 3D *p*-image (iii) for measures with significant effect of contact location in the 3D analyses. (*a*) Body bradykinesia and hypokinesia item. (*b*) Rigidity. (*c*) Tremor at rest. For the weighted mean images, the cooler shades indicate where, on average, the difference scores (ventral-OFF and dorsal-OFF) are more negative (improvement relative to OFF, for motor measures). For the 2D *p*-image, warmer shades indicate more significant *p*-values, while the cooler shades indicate less significant *p*-values. White squares indicate peak coordinates. The 3D image is shown as viewed from anteriorly, and the blue volume indicates values less than 0.05 in the *p*-image. STN, subthalamic nucleus; ZI, zona incerta, D, dorsal, V, ventral, L, lateral, M, medial. Table 3.Statistical summary of 3D analyses.^a^*p* (permu­tation)peak weighted mean valuepeak weighted mean location (*x*, *y*, *z*)peak weighted mean locationpeak in *p*-imagepeak *p*-location (*x*, *y*, *z*)peak *p*-location*movement*^b^bradykinesia0.07−6.518, −16.5, −2.5comb bundle/cp\<0.001(12.5, −17.5, −3)dorsal STNbody0.002−2.0(18, −16.5, −2.5)comb bundle/cp\<0.001(13, −20, −4)dorsal STNrigidity0.018−3.0(12, −16.5, 3.5)VLPI\<0.001(12.5, −19.5, −4)STNtremor at rest0.009−5.0(8.5, −24, −1.5)CM\<0.001(13, −20.5, −3.5)dorsal STNUPDRS total0.07−10.5(7, −21, −6)red nucleus/PBP\<0.001(12, −20.5, −3.5)ZI*mood and motivation*^c^anxiety0.70arousal0.11valence0.28apathy0.61*cognition*^d^GNG0.65SDR0.4[^14][^15][^16][^17][^18]

4.. Discussion {#s4}
==============

The results support the conclusion that 3D electrode contact location contributes to the motor effects of STN DBS. The peak *p*-values for DBS-induced improvements in motor function were located more dorsally in the STN. This confirms our findings in a different sample, using a different experimental design \[[@RSOS171177C15]\], which showed greater motor improvement in dorsolateral STN, particularly for tremor at rest. Similarly, previous studies also suggested greater improvement in motor function in dorsal STN and the zona incerta (ZI) \[[@RSOS171177C10],[@RSOS171177C26],[@RSOS171177C27]\]. These results fit with anatomical data placing the dorsolateral portion of the STN in a loop connecting primary motor cortex to putamen and motor thalamus, and linking the zona incerta to motor and limbic systems.

In the current study, electrode contact site, as a 3D variable, did not significantly alter the effect of STN DBS on cognitive or mood function in PD. However, ventral STN stimulation improved anxiety more than dorsal STN stimulation in the univariate analysis. A previous study \[[@RSOS171177C28]\] showed increased mood improvement with STN DBS in those with anxiety or mood disorders or higher symptom severity, but psychiatric diagnosis was not assessed in the present study. The non-significant association of contact location and cognitive function is surprising given the present sample size and our previous findings that DBS effects on cognitive measures were location dependent \[[@RSOS171177C6],[@RSOS171177C15]\]. However, there are several differences between the current study and the most comparable previous study \[[@RSOS171177C15]\]. First, the previous study\'s ON sessions tested participants with their individually optimized DBS settings, including choice of active contact. In other words, in that study the contact selection was not chosen blind to clinical response. Furthermore, because in that study the contacts and settings were optimized clinically, cognitive or affective responses may have contributed to selecting contact or pulse settings that were more likely to improve mood or thinking than the anatomically chosen DBS contacts and standardized pulse settings in the present study.

The strengths of this study include its relatively large sample size, acute stimulation paradigm, assessment blind to the location stimulated and innovative statistical approach. Limitations include the fact that clinical DBS electrode implantation targets the dorsal posterolateral STN, which necessarily limits the number of contacts that fall in the anterior or medial--ventral STN. The limited number of data points in these regions reflects this reality, reducing power in parts of the ventromedial and anterior STN. Second, in some conditions, participants or examiners may have detected when STN was turned on. However, as the focus of the study was the correlation of effect with DBS site, and neither the participants nor the examiners knew the precise locations of the contacts, the study was still blinded for the key variable under investigation, i.e. the location of the active contact. Third, the minimum interval between DBS changes (42 min) was chosen based on previous experience with motor signs, but there may be longer-term effects---on mood and cognitive function in particular---that this investigation may have missed. However, the time limit on the OFF session was also chosen with ethical and practical considerations in mind that preclude extending the time to study more delayed effects. Finally, statistically significant changes in rating scales may not imply syndromal or clinically significant changes. Nevertheless, UPDRS ratings are standard measures of parkinsonian severity, and VASs offer one of the few practicable options for frequent assessment of emotional state. Self-report VAS ratings have correlated well with clinical ratings of depression and anxiety severity \[[@RSOS171177C29]--[@RSOS171177C32]\].

Our previous study in a different sample of patients with PD did not support complete functional segregation within the STN of mood, motor and cognitive function \[[@RSOS171177C15]\]. This new sample provides some functional evidence for a dorsal--ventral, motor--non-motor gradient of benefit, in that the 3D analysis found significant location effects for body, rigidity and tremor at rest ([table 3](#RSOS171177TB3){ref-type="table"}), with the evidence for improvement stronger in ZI or dorsolateral STN for these measures ([table 3](#RSOS171177TB3){ref-type="table"} and [figure 2](#RSOS171177F2){ref-type="fig"}). By contrast, anxiety improved significantly more with ventral than dorsal stimulation ([table 2](#RSOS171177TB2){ref-type="table"}). On the other hand, rigidity also improved more with ventral than dorsal stimulation ([table 2](#RSOS171177TB2){ref-type="table"}); stimulation of either ventral or dorsal STN improved motor function, anxiety, valence and apathy; and cognitive effects were observed with neither stimulation site. Therefore, the direct, functional evidence supports only a mild dorsal--ventral gradient for motor and non-motor effects of STN DBS, rather than a strict dorsal--ventral functional segregation.
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